# Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

> **NCT02307643** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 17 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** MT-1303 Low dose
- **DRUG:** MT-1303 High dose

## Key facts

- **NCT ID:** NCT02307643
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307643, "Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02307643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*